Compare Adaptive Biotechnologies Corp (ADPT) vs YieldMax AMZN Option Income Strategy ETF (AMZY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs YieldMax AMZN Option Income Strategy ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.13 (market cap $3.33B), while YieldMax AMZN Option Income Strategy ETF trades at $10.68. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, YieldMax AMZN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | AMZY | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $22.37 | $16.61 |
52-Week Low | $10.24 | $10.26 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
AMZY trades at $10.74, up 0.51% today, with a bearish technical signal from moving averages. The ETF generates high weekly dividends but faces scrutiny over net asset value erosion. Recent news highlights consistent distribution announcements alongside analyst downgrades citing structural risks in its synthetic option strategy relative to Amazon's performance.
The outlook is cautious due to inevitable NAV erosion despite high yield, with total returns lagging Amazon. Risks include amplified downside exposure and unsustainable payouts. Investors prioritizing income may find appeal, but long-term capital appreciation appears constrained by the fund's design.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About YieldMax AMZN Option Income Strategy ETF
AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.
Read more on AMZY →
